Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 1, 2011, Pages 93-94

  Verslype, C ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dose escalation; Net; Octreotide

Indexed keywords

LONG ACTING OCTREOTIDE; OCTREOTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADVANCED GASTROINTESTINAL NEUROENDOCRINE TUMOR; CANCER GROWTH; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAZARD RATIO; HUMAN; LETTER; NEUROENDOCRINE TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE;

EID: 79956280308     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. VERSLYPE C., CARTON S., BORBATH I., DELAUNOIT T., DEMETTER P., DEMOLIN G., HENDLISZ A., PATTYN P., PAUWELS S., PEETERS M., ROEYEN G., VAN HOOTEGEM P., VAN LAETHEM J.L., VAN CUTSEM E. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. Acta Gastroenterol. Belg., 2009, 72: 54-8.
2. RINKE A., MÜLLER H.H., SCHADE-BRITTINGER C., KLOSE K.J., BARTH P., WIED M., MAYER C., AMINOSSADATI B., PAPE U.F., BLÄKER M., HARDER J., ARNOLD C., GRESS T., ARNOLD R.; PROMID STUDY GROUP. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol., 2009, 27: 4656-63.
3. WOLTERING E.A., SALVO V.A., O'DORISIO T.M., LYONS J. 3RD., LI G., ZHOU Y., SEWARD J.R., GO V.L., VINIK A.I., MAMIKUNIAN P., MAMIKUNIAN G. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas, 2008, 37: 94-100 and 37: 338-9 (author reply).
4. OBERG K., FERONE D., KALTSAS G., KNIGGE U.P., TAAL B., PLÖCKINGER U.; MALLORCA CONSENSUS CONFERENCE PARTICIPANTS; EUROPEAN NEUROENDOCRINE TUMOR SOCIETY. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology, 2009, 90: 209-13.
5. WELIN S.V., JANSON E.T., SUNDIN A., STRIDSBERG M., LAVENIUS E., GRANBERG D., SKOGSEID B., OBERG K.E., ERIKSSON B.K. Highdose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur. J. Endocrinol., 2004, 151: 107-12.
6. CHADHA M.K., LOMBARDO J., MASHTARE T., WILDING G.E., LITWIN A., RACZYK C., GIBBS J.F., KUVSHINOFF B., JAVLE M.M., IYER R.V. High-dose octreotide acetate for management of gastro - enteropancreatic neuroendocrine tumors. Anticancer Res., 2009, 29: 4127-30.
7. ANTHONY L.B., STAFFORD S., CRONIN M. et al. Octreotide LAR doses used in clinical practice: results from an internet survey and a clinical practice. Proc. Am. Soc. Clin. Oncol., 2004, 23: 4274.
8. CLARK O.H., BENSON A.B. 3RD., BERLIN J.D., CHOTI M.A., DOHERTY G.M., ENGSTROM P.F., GIBBS J.F., HESLIN M.J., KESSINGER A., KULKE M.H., KVOLS L., SALEM R., SALTZ L., SHAH M.H., SHIBATA S., STROSBERG J.R., YAO J.C.; NCCN NEURO - ENDOCRINE TUMORS PANEL MEMBERS. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J. Natl. Compr. Canc. Netw., 2009, 7: 712-47.
9. JANSON E.T., SØRBYE H., WELIN S., FEDERSPIEL B., GRØNBAEK H., HELLMAN P., MATHISEN O., MORTENSEN J., SUNDIN A., THIIS-EVENSEN E., VÄLIMÄKI M.J., OBERG K., KNIGGE U. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuro - endocrine tumours. Acta Oncol., 2010, 49: 740-56.